The non-invasive prenatal testing market size has grown rapidly in recent years. It will grow from $6.27 billion in 2025 to $7.21 billion in 2026 at a compound annual growth rate (CAGR) of 15%. The growth in the historic period can be attributed to growing awareness of prenatal screening, reliance on invasive diagnostic methods, increasing use of assay kits and reagents, adoption of next-generation sequencing in labs, demand for early detection of chromosomal abnormalities.
The non-invasive prenatal testing market size is expected to see rapid growth in the next few years. It will grow to $12.37 billion in 2030 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to rising adoption of non-invasive prenatal testing globally, increasing investment in advanced sequencing technologies, expansion of hospital and diagnostic lab networks, growing demand for early genetic screening, advancing integration of ai and data analytics in prenatal diagnostics. Major trends in the forecast period include rising adoption of ai-based genetic analysis, increasing use of ngs and pcr systems for prenatal testing, growing implementation of cloud-based data management in diagnostics, expanding deployment of high-throughput screening technologies, advancing integration of personalized prenatal risk assessment.
The rising maternal age is expected to drive the growth of the non-invasive prenatal testing (NIPT) market in the coming years. Factors such as extended education, career priorities, financial stability, delayed marriage, improved contraception, personal choice, and societal changes are contributing to women postponing childbirth. As maternal age increases, the risk of chromosomal abnormalities rises, leading more expectant mothers to choose NIPT for assessing fetal health. For instance, in March 2025, according to the Centers for Disease Control and Prevention, a U.S.-based government agency, the average age of mothers at first birth in 2023 rose to 27.5 years, up from 27.4 in 2022, setting another record high. Therefore, the trend of increasing maternal age is propelling the growth of the non-invasive prenatal testing market.
Major companies in the NIPT market are developing advanced solutions such as linked-SNP (single nucleotide polymorphism) technology to enhance diagnostic accuracy, improve detection of complex genetic cases, and reduce reliance on paternal samples. Linked-SNP technology analyzes genetically linked markers across the genome to infer inheritance patterns, enabling precise identification of challenging conditions like homozygous mutations. For example, in August 2025, Natera, a U.S.-based cell-free DNA (cfDNA) testing and precision medicine company, launched Fetal Focus, a NIPT for inherited single-gene disorders that screens the fetus using only maternal blood when the biological father is unavailable. The test targets five genes - CFTR, SMN1, HBA1/HBA2, and HBB - and is supported by data from the EXPAND clinical trial. In its first readout (n=101), Fetal Focus demonstrated 91% sensitivity and successfully detected all five homozygous variant fetuses, highlighting the effectiveness of its linked-SNP approach in delivering noninvasive and clinically meaningful fetal risk assessment.
In January 2024, Natera, Inc., a U.S.-based clinical genetic testing company, acquired reproductive health assets from Invitae for $42.5 million. Through this acquisition, Natera aims to expand its offerings in non-invasive prenatal and carrier screening, key components of reproductive health services. Invitae is a U.S.-based biotechnology company providing non-invasive prenatal testing solutions.
Major companies operating in the non-invasive prenatal testing market are F. Hoffmann-La Roche AG, Illumina Inc., Laboratory Corporation of America Holdings, Natera Inc., PerkinElmer Inc., Quest Diagnostics Inc., Agilent Technologies Inc., BGI Diagnosis Co Ltd., Berry Genomics Co, LifeCodexx AG, Myriad Genetics Inc., NIPD Genetics Co Ltd., Sequenom Inc., Annoroad Gene Technology Co Ltd., Centogene AG, Counsyl Inc., EUROFINS Genoma Group, Eurofins Scientific SE, Next Biosciences, Premaitha Health Plc, Ariosa Diagnostics Inc., Yourgene Health PLC, GE Healthcare Technologies Inc., Koninklijke Philips NV, Thermo Fisher Scientific Inc., Pacific Biosciences of California Inc., QIAGEN NV, MedGenome Labs Ltd., Progenity Inc., Beijing Genomics Institute.
North America was the largest region in the non-invasive prenatal testing market in 2025. Western Europe was the second largest region in the non-invasive prenatal testing market. The regions covered in the non-invasive prenatal testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the non-invasive prenatal testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have impacted the non-invasive prenatal testing market by increasing costs of imported consumables and instruments such as ngs systems, pcr machines, and assay kits. Segments including consumables and instruments are most affected, with north america, europe, and asia-pacific experiencing the highest cost pressures. While tariffs increase procurement costs and lead times, they also encourage local manufacturing, promote development of cost-efficient testing solutions, and strengthen domestic diagnostic supply chains.
The non-invasive prenatal testing market research report is one of a series of new reports that provides non-invasive prenatal testing market statistics, including non-invasive prenatal testing industry global market size, regional shares, competitors with a non-invasive prenatal testing market share, detailed non-invasive prenatal testing market segments, market trends and opportunities, and any further data you may need to thrive in the non-invasive prenatal testing industry. This non-invasive prenatal testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Non-invasive prenatal testing is a procedure in which maternal blood is collected and analyzed to detect potential abnormalities in the fetus. These testing kits and equipment are primarily used to identify genetic abnormalities, particularly chromosomal defects, during the first trimester of pregnancy.
The main types of non-invasive prenatal testing include consumables and instruments. Consumables are items that are used up or depleted during testing, while instruments include NGS systems, PCR machines, microarrays, ultrasound devices, and other equipment such as centrifuges, UV systems, incubators, and microscopes. Consumables include assay kits, reagents, and disposables. Applications of these tests cover trisomy, microdeletions, genetic screening, and Rh factor determination, and they are used by hospitals and diagnostic laboratories.
The non-invasive prenatal testing market includes revenue earned by ultrasound detection, fetal cells in maternal blood tests, cell-free DNA in maternal plasma tests, and biochemical screening tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The non-invasive prenatal testing market size is expected to see rapid growth in the next few years. It will grow to $12.37 billion in 2030 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to rising adoption of non-invasive prenatal testing globally, increasing investment in advanced sequencing technologies, expansion of hospital and diagnostic lab networks, growing demand for early genetic screening, advancing integration of ai and data analytics in prenatal diagnostics. Major trends in the forecast period include rising adoption of ai-based genetic analysis, increasing use of ngs and pcr systems for prenatal testing, growing implementation of cloud-based data management in diagnostics, expanding deployment of high-throughput screening technologies, advancing integration of personalized prenatal risk assessment.
The rising maternal age is expected to drive the growth of the non-invasive prenatal testing (NIPT) market in the coming years. Factors such as extended education, career priorities, financial stability, delayed marriage, improved contraception, personal choice, and societal changes are contributing to women postponing childbirth. As maternal age increases, the risk of chromosomal abnormalities rises, leading more expectant mothers to choose NIPT for assessing fetal health. For instance, in March 2025, according to the Centers for Disease Control and Prevention, a U.S.-based government agency, the average age of mothers at first birth in 2023 rose to 27.5 years, up from 27.4 in 2022, setting another record high. Therefore, the trend of increasing maternal age is propelling the growth of the non-invasive prenatal testing market.
Major companies in the NIPT market are developing advanced solutions such as linked-SNP (single nucleotide polymorphism) technology to enhance diagnostic accuracy, improve detection of complex genetic cases, and reduce reliance on paternal samples. Linked-SNP technology analyzes genetically linked markers across the genome to infer inheritance patterns, enabling precise identification of challenging conditions like homozygous mutations. For example, in August 2025, Natera, a U.S.-based cell-free DNA (cfDNA) testing and precision medicine company, launched Fetal Focus, a NIPT for inherited single-gene disorders that screens the fetus using only maternal blood when the biological father is unavailable. The test targets five genes - CFTR, SMN1, HBA1/HBA2, and HBB - and is supported by data from the EXPAND clinical trial. In its first readout (n=101), Fetal Focus demonstrated 91% sensitivity and successfully detected all five homozygous variant fetuses, highlighting the effectiveness of its linked-SNP approach in delivering noninvasive and clinically meaningful fetal risk assessment.
In January 2024, Natera, Inc., a U.S.-based clinical genetic testing company, acquired reproductive health assets from Invitae for $42.5 million. Through this acquisition, Natera aims to expand its offerings in non-invasive prenatal and carrier screening, key components of reproductive health services. Invitae is a U.S.-based biotechnology company providing non-invasive prenatal testing solutions.
Major companies operating in the non-invasive prenatal testing market are F. Hoffmann-La Roche AG, Illumina Inc., Laboratory Corporation of America Holdings, Natera Inc., PerkinElmer Inc., Quest Diagnostics Inc., Agilent Technologies Inc., BGI Diagnosis Co Ltd., Berry Genomics Co, LifeCodexx AG, Myriad Genetics Inc., NIPD Genetics Co Ltd., Sequenom Inc., Annoroad Gene Technology Co Ltd., Centogene AG, Counsyl Inc., EUROFINS Genoma Group, Eurofins Scientific SE, Next Biosciences, Premaitha Health Plc, Ariosa Diagnostics Inc., Yourgene Health PLC, GE Healthcare Technologies Inc., Koninklijke Philips NV, Thermo Fisher Scientific Inc., Pacific Biosciences of California Inc., QIAGEN NV, MedGenome Labs Ltd., Progenity Inc., Beijing Genomics Institute.
North America was the largest region in the non-invasive prenatal testing market in 2025. Western Europe was the second largest region in the non-invasive prenatal testing market. The regions covered in the non-invasive prenatal testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the non-invasive prenatal testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have impacted the non-invasive prenatal testing market by increasing costs of imported consumables and instruments such as ngs systems, pcr machines, and assay kits. Segments including consumables and instruments are most affected, with north america, europe, and asia-pacific experiencing the highest cost pressures. While tariffs increase procurement costs and lead times, they also encourage local manufacturing, promote development of cost-efficient testing solutions, and strengthen domestic diagnostic supply chains.
The non-invasive prenatal testing market research report is one of a series of new reports that provides non-invasive prenatal testing market statistics, including non-invasive prenatal testing industry global market size, regional shares, competitors with a non-invasive prenatal testing market share, detailed non-invasive prenatal testing market segments, market trends and opportunities, and any further data you may need to thrive in the non-invasive prenatal testing industry. This non-invasive prenatal testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Non-invasive prenatal testing is a procedure in which maternal blood is collected and analyzed to detect potential abnormalities in the fetus. These testing kits and equipment are primarily used to identify genetic abnormalities, particularly chromosomal defects, during the first trimester of pregnancy.
The main types of non-invasive prenatal testing include consumables and instruments. Consumables are items that are used up or depleted during testing, while instruments include NGS systems, PCR machines, microarrays, ultrasound devices, and other equipment such as centrifuges, UV systems, incubators, and microscopes. Consumables include assay kits, reagents, and disposables. Applications of these tests cover trisomy, microdeletions, genetic screening, and Rh factor determination, and they are used by hospitals and diagnostic laboratories.
The non-invasive prenatal testing market includes revenue earned by ultrasound detection, fetal cells in maternal blood tests, cell-free DNA in maternal plasma tests, and biochemical screening tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Non-invasive Prenatal Testing Market Characteristics
3. Non-invasive Prenatal Testing Market Supply Chain Analysis
4. Global Non-invasive Prenatal Testing Market Trends and Strategies
5. Non-invasive Prenatal Testing Market Analysis of End Use Industries
7. Global Non-invasive Prenatal Testing Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Non-invasive Prenatal Testing Total Addressable Market (TAM) Analysis for the Market
9. Non-invasive Prenatal Testing Market Segmentation
10. Non-invasive Prenatal Testing Market Regional and Country Analysis
11. Asia-Pacific Non-invasive Prenatal Testing Market
12. China Non-invasive Prenatal Testing Market
13. India Non-invasive Prenatal Testing Market
14. Japan Non-invasive Prenatal Testing Market
15. Australia Non-invasive Prenatal Testing Market
16. Indonesia Non-invasive Prenatal Testing Market
17. South Korea Non-invasive Prenatal Testing Market
18. Taiwan Non-invasive Prenatal Testing Market
19. South East Asia Non-invasive Prenatal Testing Market
20. Western Europe Non-invasive Prenatal Testing Market
21. UK Non-invasive Prenatal Testing Market
22. Germany Non-invasive Prenatal Testing Market
23. France Non-invasive Prenatal Testing Market
24. Italy Non-invasive Prenatal Testing Market
25. Spain Non-invasive Prenatal Testing Market
26. Eastern Europe Non-invasive Prenatal Testing Market
27. Russia Non-invasive Prenatal Testing Market
28. North America Non-invasive Prenatal Testing Market
29. USA Non-invasive Prenatal Testing Market
30. Canada Non-invasive Prenatal Testing Market
31. South America Non-invasive Prenatal Testing Market
32. Brazil Non-invasive Prenatal Testing Market
33. Middle East Non-invasive Prenatal Testing Market
34. Africa Non-invasive Prenatal Testing Market
36. Non-invasive Prenatal Testing Market Competitive Landscape and Company Profiles
37. Non-invasive Prenatal Testing Market Other Major and Innovative Companies
40. Non-invasive Prenatal Testing Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Non-invasive Prenatal Testing Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses non-invasive prenatal testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for non-invasive prenatal testing? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The non-invasive prenatal testing market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Consumables; Instruments2) By Application: Trisomy; Microdeletion; Genetics; Rh factor
3) By End User: Hospital; Diagnostic Labs
Subsegments:
1) By Consumables: Assay Kits; Reagents; Disposables2) By Instruments: Next-Generation Sequencers (NGS); Polymerase Chain Reaction (PCR) Systems; Ultrasound Devices
Companies Mentioned: F. Hoffmann-La Roche AG; Illumina Inc.; Laboratory Corporation of America Holdings; Natera Inc.; PerkinElmer Inc.; Quest Diagnostics Inc.; Agilent Technologies Inc.; BGI Diagnosis Co Ltd.; Berry Genomics Co; LifeCodexx AG; Myriad Genetics Inc.; NIPD Genetics Co Ltd.; Sequenom Inc.; Annoroad Gene Technology Co Ltd.; Centogene AG; Counsyl Inc.; EUROFINS Genoma Group; Eurofins Scientific SE; Next Biosciences; Premaitha Health Plc; Ariosa Diagnostics Inc.; Yourgene Health PLC; GE Healthcare Technologies Inc.; Koninklijke Philips NV; Thermo Fisher Scientific Inc.; Pacific Biosciences of California Inc.; QIAGEN NV; MedGenome Labs Ltd.; Progenity Inc.; Beijing Genomics Institute
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Non-invasive Prenatal Testing market report include:- F. Hoffmann-La Roche AG
- Illumina Inc.
- Laboratory Corporation of America Holdings
- Natera Inc.
- PerkinElmer Inc.
- Quest Diagnostics Inc.
- Agilent Technologies Inc.
- BGI Diagnosis Co Ltd.
- Berry Genomics Co
- LifeCodexx AG
- Myriad Genetics Inc.
- NIPD Genetics Co Ltd.
- Sequenom Inc.
- Annoroad Gene Technology Co Ltd.
- Centogene AG
- Counsyl Inc.
- EUROFINS Genoma Group
- Eurofins Scientific SE
- Next Biosciences
- Premaitha Health Plc
- Ariosa Diagnostics Inc.
- Yourgene Health PLC
- GE Healthcare Technologies Inc.
- Koninklijke Philips NV
- Thermo Fisher Scientific Inc.
- Pacific Biosciences of California Inc.
- QIAGEN NV
- MedGenome Labs Ltd.
- Progenity Inc.
- Beijing Genomics Institute
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 7.21 Billion |
| Forecasted Market Value ( USD | $ 12.37 Billion |
| Compound Annual Growth Rate | 14.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 31 |
